cmi_logo.png
[Latest] Global Glycomics Market Size/Share Worth USD 5.2 Billion by 2033 at a 13.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
05 juil. 2024 03h30 HE | Custom Market Insights
Austin, TX, USA, July 05, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Glycomics Market Size, Trends and Insights By Product Type (Reagents, Enzymes,...
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
27 juin 2024 05h00 HE | ANEW MEDICAL, INC.
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
26 juin 2024 05h00 HE | ANEW MEDICAL, INC.
ANEW MEDICAL, INC. SECURES KEY PATENT IN EUROPE FOR HUMAN KLOTHO GENE RNA SLICE VARIANT AND PROTEIN
Clearside Logo 2024.jpg
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
12 juin 2024 07h05 HE | Clearside Biomedical, Inc.
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ...
Soligenix
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
05 juin 2024 08h00 HE | PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
Kymanox® Announces F
Kymanox® Announces Facility Expansion to Enhance CGxP Space and Laboratory Service Offerings
03 juin 2024 10h16 HE | Kymanox
King of Prussia, Pennsylvania USA, June 03, 2024 (GLOBE NEWSWIRE) -- Kymanox is pleased to announce the expansion of its device design and testing facility in King of Prussia (KOP), PA, which will...
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
22 mai 2024 08h30 HE | Biodexa Pharmaceuticals PLC
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...
PMV main logo.png
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
21 mai 2024 12h35 HE | PRISM MarketView
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
PaxMedica logo.jpg
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
15 mai 2024 08h30 HE | PaxMedica, Inc.
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for...
biodexa-logo-square (1).png
Posting of Annual Report & Notice of AGM - Total Voting Rights
15 mai 2024 03h58 HE | Biodexa Pharmaceuticals PLC
May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...